Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
55 clinical trials · Sponsor
◉ Watch Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
| Record | Firm | Date |
|---|---|---|
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) (NCT07499362) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2026-03-26 |
| A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (NCT07340827) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2026-02-04 |
| An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (NCT07269327) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2025-11-24 |
| Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (NCT06806046) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-12-20 |
| Effect of Renal Impairment on Enpatoran Pharmacokinetics (NCT06589713) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-09-24 |
| Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants (NCT06577337) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-09-12 |
| A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants (NCT06589726) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-09-10 |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) (NCT06463587) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-06-25 |
| JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study (NCT06412848) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-05-09 |
| Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) (NCT06308263) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2024-03-25 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) (NCT05974267) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-11-28 |
| Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA) (NCT05797740) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-08-03 |
| Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) (NCT05689047) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-03-29 |
| Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong) (NCT05930808) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-02-28 |
| Mirdametinib + BGB-3245 in Advanced Solid Tumors (NCT05580770) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2023-02-03 |
| Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) (NCT05650164) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-01-25 |
| Relative Bioavailability of Evobrutinib Tablet Batches (NCT07214922) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2023-01-18 |
| A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD (NCT05655832) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-12-05 |
| A TQT Study of Effect of M2951 on Cardiac Repolarization (NCT07214935) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-11-08 |
| PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants (NCT05519540) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-09-26 |
| The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) (NCT05540327) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-09-16 |
| Nirogacestat in Ovarian Granulosa Cell Tumors (NCT05348356) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-08-30 |
| Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive (NCT07215806) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-08-24 |
| GXR RM China BE Study (Darmstadt - Jiangsu) (NCT05463094) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-07-25 |
| A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread (NCT05431777) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-07-19 |
| A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy (NCT05366725) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-06-29 |
| Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) (NCT05246111) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-02-15 |
| Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants (NCT05245396) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-02-02 |
| Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants (NCT05203822) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-01-21 |
| DDI Study of Evobrutinib and Carbamazepine (NCT05248945) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-01-13 |
| BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites) (NCT05174000) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2022-01-10 |
| Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants (NCT05213481) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-12-15 |
| Enpatoran Human Mass Balance and Absolute Bioavailability Study (NCT05110027) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-11-05 |
| Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates (NCT05064488) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-10-04 |
| Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS) (NCT04997148) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-08-11 |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) (NCT04941768) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-08-09 |
| Pergoveris FD and Liquid China BE Study (NCT04899193) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-05-08 |
| Study of M5049 in Healthy Japanese and Caucasian Participants (NCT04880213) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-05-06 |
| Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) (NCT04783935) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-03-10 |
| Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) (NCT04776213) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-02-23 |
| Effect of Food on Peposertib PK (NCT04702698) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-01-14 |
| Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants (NCT04697511) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2021-01-11 |
| GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study (NCT04684420) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-12-22 |
| Study of M5049 in CLE and SLE Participants (NCT04647708) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-12-16 |
| Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK (NCT04546789) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-09-30 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 2) (NCT04338061) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-07-02 |
| Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide (NCT04314037) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-06-17 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 1) (NCT04338022) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-06-12 |
| Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets (NCT04314024) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-05-25 |
| Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model (NCT04250363) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-02-17 |
| Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS) (NCT04934800) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-12-10 |
| A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers (NCT03979274) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-12-06 |
| Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib (NCT04204902) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-10-17 |
| Deflox Tablets Bioequivalence (BE) Trial (NCT04132583) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-09-21 |
| Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form (NCT04037748) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-06-25 |
| Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (NCT03785964) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2019-04-17 |
| Effect of Meal Composition and Timing on Evobrutinib Bioavailability (NCT03934502) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2019-04-15 |
Track Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany automatically
Every clearance here is in the API, with alerts when new ones post.